Raymond James Financial Inc. Buys New Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Raymond James Financial Inc. acquired a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 92,904 shares of the company's stock, valued at approximately $3,450,000. Raymond James Financial Inc. owned 0.19% of Amphastar Pharmaceuticals as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Pacer Advisors Inc. grew its position in Amphastar Pharmaceuticals by 51,977.4% in the fourth quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock valued at $50,139,000 after acquiring an additional 1,347,775 shares during the last quarter. Boston Trust Walden Corp lifted its stake in Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after buying an additional 439,281 shares during the period. Renaissance Technologies LLC lifted its stake in Amphastar Pharmaceuticals by 7.4% in the fourth quarter. Renaissance Technologies LLC now owns 525,500 shares of the company's stock valued at $19,512,000 after buying an additional 36,100 shares during the period. Boston Partners bought a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter valued at approximately $15,778,000. Finally, Nordea Investment Management AB increased its holdings in shares of Amphastar Pharmaceuticals by 4.8% during the fourth quarter. Nordea Investment Management AB now owns 279,714 shares of the company's stock valued at $10,386,000 after acquiring an additional 12,851 shares in the last quarter. Institutional investors own 65.09% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AMPH. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Piper Sandler dropped their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st.

Amphastar Pharmaceuticals Trading Up 0.4 %

Shares of Amphastar Pharmaceuticals stock traded up $0.09 during trading on Tuesday, reaching $24.50. The company's stock had a trading volume of 296,382 shares, compared to its average volume of 465,082. Amphastar Pharmaceuticals, Inc. has a 52-week low of $22.64 and a 52-week high of $53.96. The company has a market cap of $1.16 billion, a price-to-earnings ratio of 8.17, a PEG ratio of 2.19 and a beta of 0.79. The firm's 50-day moving average is $26.91 and its two-hundred day moving average is $36.27. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Insider Activity at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares of the company's stock, valued at $2,681,377.02. The trade was a 4.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 27.10% of the stock is owned by company insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.